Chang, Ting-YuTing-YuChangJUNG-YIEN CHIENWu, Chung-HsuenChung-HsuenWuDong, Yaa-HuiYaa-HuiDongFANG-JU LIN2020-10-122020-10-122020-0500123692https://scholars.lib.ntu.edu.tw/handle/123456789/516778The differential risk of pneumonia among inhaled corticosteroid (ICS) use in patients with COPD requires more investigation, especially regarding beclomethasone-containing inhalers. The goal of this study was to compare the risk and benefit profile of different ICS/long-acting β2-agonist (LABA) combinations in patients with COPD.COPD; acute exacerbation; inhaled corticosteroids; pneumonia[SDGs]SDG3beclometasone; beta 2 adrenergic receptor stimulating agent; budesonide plus formoterol; corticosteroid; fluticasone propionate plus salmeterol; formoterol; beclometasone; beta 2 adrenergic receptor stimulating agent; bronchodilating agent; budesonide; corticosteroid; fluticasone; formoterol fumarate; glucocorticoid; salmeterol xinafoate; aged; Article; chronic obstructive lung disease; cohort analysis; comparative study; disease exacerbation; disease severity; drug efficacy; drug safety; female; follow up; hazard ratio; human; major clinical study; male; outcome assessment; pneumonia; priority journal; propensity score; proportional hazards model; retrospective study; risk benefit analysis; sensitivity analysis; Taiwan; chronic obstructive lung disease; combination drug therapy; drug combination; inhalational drug administration; metered dose inhaler; middle aged; Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Aged; Beclomethasone; Bronchodilator Agents; Budesonide; Drug Combinations; Drug Therapy, Combination; Female; Fluticasone; Formoterol Fumarate; Glucocorticoids; Humans; Male; Metered Dose Inhalers; Middle Aged; Pneumonia; Propensity Score; Pulmonary Disease, Chronic Obstructive; Retrospective Studies; Salmeterol Xinafoate; Taiwanjournal article10.1016/j.chest.2019.12.00631887282WOS:000532715300025